The author recently reviewed therapeutic strategies in AML, highlighting kinase pathways such as FLT3, PI3K/AKT/mTOR, CDK, and CHK1, and emphasizing the potential of combination therapies over monotherapies [50]. This evidence concerns the gene AKT1 and acute myeloid leukemia.